Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jul 24;2:PO.18.00036. doi: 10.1200/PO.18.00036

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

Fig 5. — Favorable prognosis in high-risk prostate-specific antigen (PSA) subgroup in the SPOP mutant (SPOPmut) subclass. (A) Clinical outcome difference between lower, average, and higher PSA groups via Kaplan-Meier analyses for metastasis (MET) and prostate cancer–specific mortality (PCSM) –free survival rates. (B) Significant clinical outcome difference between SPOPmut and wild-type (wt) subclasses via Kaplan-Meier analysis of MET- and PCSM-free survival rates. (C) Significant clinical outcome difference between lower PSA (PSA < 10 ng/mL) and SPOP wild type (SPOPwt) subclass within higher PSA (PSA > 20 ng/mL) groups via Kaplan-Meier analysis of MET- and PCSM-free survival rates. (D) No clinical outcome difference between lower PSA (PSA < 10 ng/mL) and SPOPmut subclass within higher PSA (PSA > 20 ng/mL) groups via Kaplan-Meier analysis of MET- and PCSM-free survival rates.